^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Other names: BGB-A317, BGB A317, VDT482, BGBA317, VDT 482, VDT-482
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    2d
    INDIE: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, University of Cologne | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tevimbra (tislelizumab-jsgr)
    5d
    PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis. (PubMed, Clin Cancer Res)
    Tislelizumab with chemotherapy/chemoradiotherapy as neoadjuvant treatment for resectable ESCC yielded promising pCR rates and favorable survival outcomes with a tolerable safety profile in both PET-/CT-guided responders and PET nonresponders.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr)
    7d
    A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    8d
    Pathological complete response in esophageal squamous cell carcinoma complicated by malignant fistula via neoadjuvant immunotherapy, chemoradiotherapy, and nutritional support: a case report. (PubMed, Front Immunol)
    This allowed the patient to successfully complete neoadjuvant therapy consisting of the anti-PD-1 antibody tislelizumab, paclitaxel, carboplatin, and concurrent intensity-modulated radiation therapy (IMRT). Immunohistochemical analysis of pre-treatment biopsies demonstrated PD-L1 positivity and high infiltration of CD8+ T cells, suggesting that a robust immune-active microenvironment favored the efficacy of PD-1 blockade. This case underscores the feasibility of integrating immunotherapy with chemoradiotherapy in ESCC patients complicated by esophageal fistulas when supported by rigorous nutritional management.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr)
    9d
    FMT-LUNG: Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Se-Hoon Lee
    New P2 trial • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Tevimbra (tislelizumab-jsgr)
    10d
    Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer (clinicaltrials.gov)
    P=N/A, N=94, Recruiting, Zhejiang Provincial People's Hospital | Not yet recruiting --> Recruiting | N=55 --> 94
    Enrollment open • Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    RET fusion • ALK fusion • NTRK fusion
    |
    Tevimbra (tislelizumab-jsgr) • Jiataile (sacituzumab tirumotecan)
    12d
    Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Chongqing University Cancer Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr)
    15d
    Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr)
    16d
    What is new in the German S3 guideline on gastric cancer: diagnosis, staging and treatment. (PubMed, Oncol Res Treat)
    The updated S3 guideline reflects the latest advances in diagnostics, improved palliative therapies, and supportive care. The objectives are to improve the quality of individual and broad care and to ensure consistent, evidence-based treatment strategies.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CLDN18 (Claudin 18)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tevimbra (tislelizumab-jsgr) • Vyloy (zolbetuximab-clzb)
    16d
    Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib)
    17d
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) (clinicaltrials.gov)
    P3, N=574, Not yet recruiting, RemeGen Co., Ltd.
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin)